Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | Promising results for venetoclax combination therapies in elderly AML

Marina Konopleva • 5 Oct 2017
ESH 2017
Acute Myeloid Leukemia Azacitidine Cytarabine Decitabine Venetoclax

In this exciting interview, Marina Konopleva, MD, PhD of the MD Anderson Cancer Center, Houston, TX, provides optimistic preliminary results from clinical trials (NCT02287233 and NCT02203773) utilizing venetoclax in elderly acute myeloid leukemia (AML) patients. Thus, Dr Konopleva is hopeful for the approval of venetoclax in combination therapies for AML. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).

More from Marina Konopleva

2:41
Advancements in AML: an update from ASH 2023
Marina Konopleva • 8 Dec 2023
1:36
The synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating AML
Marina Konopleva • 8 Dec 2023
1:03
10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
Marina Konopleva • 8 Dec 2023
1:17
Targeting mitochondrial metabolism to eradicate MRD in AML
Marina Konopleva • 8 Dec 2023

Related Videos

2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
3:12
An epitope editing approach to enable the use of targeted immunotherapy in AML
Gabriele Casirati • 9 Apr 2024
0:59
Developing LSC-targeting agents in AML: progress and current therapeutic capacity
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals